Cryoprecipitate Dosing for Fibrinogen Replacement
ورودیهای بالینی بیمار
حداقل ۱ — حداکثر ۳۰۰ • واحد: kg
حداقل ۰.۱۵ — حداکثر ۰.۶۵ • واحد: decimal
حداقل ۰ — حداکثر ۱۰۰۰ • واحد: mg/dL
حداقل ۵۰ — حداکثر ۵۰۰ • واحد: mg/dL
حداقل ۱۵۰ — حداکثر ۳۰۰ • واحد: mg
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Dose1–5
- Standard Dose6–15
- High Dose16–30
- Very High Dose31–100
The Cryoprecipitate Dosing for Fibrinogen Replacement calculator is designed for bedside calculating the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia in clinical practice. The resulting score directly guides clinician decision-making regarding initiating targeted anticoagulation.
Clinical Guidelines & Evidence
Calculates the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia
Clinical Indication
The Cryoprecipitate Dosing for Fibrinogen Replacement is indicated for bedside clinical practice to support Calculates the required dose of cryoprecipitate units needed to achieve target fibrinogen levels in patients with fibrinogen deficiency or hypofibrinogenemia. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Required Units = (Target Fibrinogen - Current Fibrinogen) × Plasma Volume / Fibrinogen per Unit; where Plasma Volume (dL) = Weight (kg) × Factor × (1 - Hematocrit); Factor = 0.07 for males, 0.065 for females
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| patient_weight | float | Yes | Patient weight in kilograms(kg) |
| patient_sex | string | Yes | Patient biological sex for plasma volume calculation |
| hematocrit | float | Yes | Current hematocrit as decimal (e.g., 0.40 for 40%)(decimal) |
| current_fibrinogen | float | Yes | Current fibrinogen level(mg/dL) |
| target_fibrinogen | float | Yes | Target fibrinogen level to achieve(mg/dL) |
| fibrinogen_per_unit | float | No | Fibrinogen content per cryoprecipitate unit (default 200 mg)(mg) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–5 | Low Dose | Small fibrinogen replacement |
| 6–15 | Standard Dose | Typical therapeutic replacement |
| 16–30 | High Dose | Large fibrinogen replacement |
| 31–100 | Very High Dose | Massive fibrinogen replacement |
Evidence-Based References (EBM)
- American Association of Blood Banks (AABB). Technical Manual, 20th Edition. 2020.
- British Committee for Standards in Haematology (BCSH). Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126(1):11-28.
- Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126(1):139-152.
- American Red Cross. Circular of Information for the Use of Human Blood and Blood Components. 2017.